Bharathi Shrikanth Gadad, Parvathy K. Subramanya, Srinivas Pullabhatla, Indi S. Shantharam and Rao K.S. Pages 76 - 84 ( 9 )
α-Synuclein aggregation is centrally implicated in Parkinsons disease (PD). It involves multi-step nucleated polymerization process via the formation of dimers, soluble toxic oligomers and insoluble fibrils. In the present study, we synthesized a novel compound viz., Curcumin-glucoside (Curc-gluc), a modified form of curcumin and studied its anti-aggregating potential with α-synuclein. Under aggregating conditions in vitro, Curc-gluc prevents oligomer formation as well as inhibits fibril formation indicating favorable stoichiometry for inhibition. The binding efficacies of Curc-gluc to both α-synuclein monomeric and oligomeric forms were characterized by micro-calorimetry. It was observed that titration of Curc-gluc with α-synuclein monomer yielded very low heat values with low binding while, in case of oligomers, Curc-gluc showed significant binding. Addition of Curc-gluc inhibited aggregation in a dosedependent manner and enhanced α-synuclein solubility, which propose that Curc-gluc solubilizes the oligomeric form by disintegrating preformed fibrils and this is a novel observation. Overall, the data suggest that Curc-gluc binds to α-synuclein oligomeric form and prevents further fibrillization of α-synuclein; this might aid the development of disease modifying agents in preventing or treating PD.
Alpha-synuclein,Parkinson's disease,curcumin-glucoside,oligomer,aggregation,diferulomethane,Thioflavin,Fluorescence,sonication,Tris buffer
, , , , Institute for Scientific Research and Technology Services (INDICASAT) National Secretariat for Science, Technology and Innovation Building 219, Clayton,City of Knowledge Postal address: 0843-01103 Republic of Panama.